FINAL DAYS 13TH ANNUAL TO REGISTER COVER CONFERENCE-AT-A-GLANCE SPONSORS May 1-5, 2017 • Seaport World Trade Center SHORT COURSES TRAINING SEMINARS ENGINEERING THE ESSENTIAL PROTEIN ENGINEERING SUMMIT STREAM ONCOLOGY STREAM PLENARY KEYNOTE: EVENT FEATURES: IMMUNOTHERAPY STREAM Sir Gregory Winter, Ph.D., NEW Young Scientist Keynote Presentation FRS, Master, Trinity College and 2,200+ Global 19 Short Courses EXPRESSION STREAM Co-Founder and Director, Bicycle Attendees 325+ Influential Therapeutics 22 Conference Speakers ANALYTICAL Tracks STREAM 100+ Exhibiting 6 Training Seminars Companies IMMUNOGENICITY & BIOASSAY STREAM BIOCONJUGATES STREAM THERAPEUTICS STREAM SPONSOR & EXHIBITOR INFO HOTEL & TRAVEL REGISTRATION INFORMATION Register Online! PEGSummit.com Premier Sponsors A Division of Cambridge Innovation Institute PEGSummit.com | 1 FINAL DAYS TO REGISTER CONFERENCE AT A GLANCE COVER CONFERENCE-AT-A-GLANCE SPONSORS SHORT COURSES SUNDAY MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY TRAINING SEMINARS April 29 May 1 May 2 May 3 May 4 May 5 ENGINEERING Engineering Display of Antibodies Engineering Antibodies STREAM Bispecific Antibodies ONCOLOGY Antibodies for Advancing Bispecific Antibodies ADCs II: STREAM Cancer Therapy to the Clinic for Oncology Advancing Toward the Clinic IMMUNOTHERAPY Preventing Toxicity Adoptive Agonist STREAM in Immunotherapy T-Cell Therapy Immunotherapy Targets Optimizing Protein Expression EXPRESSION Difficult to Express Proteins STREAM Protein Expression System Engineering ANALYTICAL Characterization Biophysical Analysis of Protein Aggregation STREAM of Biotherapeutics Biotherapeutics and Stability IMMUNOGENICITY & Immunogenicity: Regulatory Strategies for Immunogenicity Optimizing Bioassays for BIOASSAY STREAM and Clinical Relevance Assay Assessment Biologics ADCs I: New Targets, Payloads ADCs II: BIOCONJUGATES Fusion Protein Therapeutics STREAM and Alternative Formats Advancing Toward the Clinic THERAPEUTICS Drug Discovery for Biologics and Vaccines Agonist Immunotherapy STREAM Autoimmunity and Inflammation for Infectious Disease Targets SPONSOR & EXHIBITOR INFO Dinner Dinner Short Courses* Short Courses* HOTEL & TRAVEL Cambridge Healthtech Immunology for Drug REGISTRATION INFORMATION Discovery Scientists Regulatory Requirements Across Introduction to Structure-Based PRE-CONFERENCE SHORT COURSES* Introduction to Protein Engineering Register Online! the Product Development Lifecycle Drug Design and Development PEGSummit.com Introduction to Immunogenicity Next-Generation Sequencing for Antibody Discovery & Engineering A Division of Cambridge Innovation Institute *Separate Registration Required PEGSummit.com | 2 FINAL DAYS PEGS SPONSORS TO REGISTER Premier Sponsors COVER CONFERENCE-AT-A-GLANCE SPONSORS SHORT COURSES TRAINING SEMINARS Corporate Sponsors ENGINEERING STREAM ONCOLOGY STREAM IMMUNOTHERAPY STREAM Crystal EXPRESSION B ioscience STREAM ANALYTICAL STREAM IMMUNOGENICITY & BIOASSAY STREAM BIOCONJUGATES STREAM THERAPEUTICS STREAM SPONSOR & EXHIBITOR INFO HOTEL & TRAVEL REGISTRATION INFORMATION Register Online! PEGSummit.com Corporate Support Sponsors A Division of Cambridge Innovation Institute PEGSummit.com | 3 FINAL DAYS PLENARY KEYNOTE SESSION TO REGISTER Monday, May 1 | 4:00 - 5:40 pm COVER Bicycles and Bicycle Drug Conjugates: Next Young Scientist Keynote: Programming Proteins by CONFERENCE-AT-A-GLANCE Generation Therapeutics Deep Sequencing and Design SPONSORS Sir Gregory Winter, Ph.D., Tim Whitehead, Ph.D., FRS, Master, Trinity College and Co-Founder and Assistant Professor, Chemical Engineering and Materials SHORT COURSES Director, Bicycle Therapeutics Science, Michigan State University Bicycles® are a novel therapeutic class of constrained bicyclic peptides Next-generation sequencing has presented protein scientists with the TRAINING SEMINARS that combine antibody-like affinity and selectivity with small molecule-like ability to observe entire populations of molecules before, during, and after tissue penetration, tunable exposure and chemical synthesis. They have a high-throughput screen or selection for function. My group leverages this potential in many indications, including oncology, where Bicycles’ unique unprecedented wealth of sequence-function information to design and ENGINEERING properties have been used to develop Bicycle Drug Conjugates™ (BDCs); engineer protein affinity, specificity, and function and to infer structural STREAM a novel toxin delivery platform which greatly improves toxin loading into complexes of proteins. My talk will present an overview of the above and detail tumour tissues. This presentation will describe both the Bicycle® and BDC methodological improvements that enable the engineering work. ONCOLOGY platforms. STREAM About About Tim Whitehead is an Assistant Professor at Michigan State University in the IMMUNOTHERAPY Sir Gregory Winter is the Master of Trinity College Cambridge and was Departments of Chemical Engineering and Materials Science, Biomedical STREAM until recently a member of the Medical Research Council Laboratory of Engineering, and Biosystems Engineering. He has won an NSF CAREER award, Molecular Biology (LMB) in Cambridge, U.K., and has served as both Deputy holds 6 patents (5 licensed), and has published over 30 research articles in and Acting Director. He was one of the early pioneers of the science of journals like Science, Nature Biotechnology, and Nature Methods. EXPRESSION protein engineering, focusing first on enzymes (with Alan Fersht) and STREAM then antibodies. In particular he invented techniques to humanise rodent The PEGS Young Scientist Keynote antibodies for use as therapeutics, in the course of which he helped to The PEGS Boston Young Scientist Keynote recognizes a rising star in the ANALYTICAL develop alemtuzumab/Campath-1H. Later, he developed methods to field of protein science who has completed a postdoc in the last five years. STREAM make fully human antibodies against human self-antigens using antibody Nominations of candidates for this role were solicited from leading industry libraries. His inventions are used in most of the antibody products on the and academic research labs in the fall of 2016, and the final selection was IMMUNOGENICITY & market, including the humanised antibodies alemtuzumab/Campath-1H, made on the basis of input provided by a 14-person group of scientific BIOASSAY STREAM trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and advisors. the first human antibody (adalimumab/Humira) to be approved by the U.S. CHI’s Young Scientist Keynotes join the company’s Student Fellowships and Food and Drug Administration. Featured Poster Presentations as ways of supporting the increased visibility BIOCONJUGATES of those new to our field. Please visit the PEGS website following the 2017 STREAM Sir Gregory has also acted as an entrepreneur to translate his scientific meeting for details on how you can nominate a candidate for the 2018 inventions to medicines. He was a founder of Cambridge Antibody meeting. THERAPEUTICS Technology (1989) and Domantis (2000) and Bicycle Therapeutics STREAM (2009); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics including adalimumab/Humira and SPONSOR & EXHIBITOR INFO belimumab/Benlysta. HOTEL & TRAVEL REGISTRATION INFORMATION Register Online! PEGSummit.com A Division of Cambridge Innovation Institute PEGSummit.com | 4 FINAL DAYS TO REGISTER SHORT COURSES* COVER SUNDAY, APRIL 30 CONFERENCE-AT-A-GLANCE MORNING 10:00 AM - 1:00 PM AFTERNOON 2:00 - 5:00 PM SPONSORS SC1: Preclinical and Clinical Immunogenicity Bioanalysis: ADCs, SC7: Translational Considerations for Development of Monoclonal SHORT COURSES Multi-Domain Biotherapeutics and New Modalities Antibodies Part II: Focus on Nonclinical Development to the Clinic Darshana Jani, M.S., Senior Manager, Pfizer, Inc. Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis TRAINING SEMINARS Seema Kumar, Ph.D., Associate Director, EMD Serono Pharmaceuticals Corinna Krinos Fiorotti, Ph.D., Business Development Manager, Bioagilytix Enrique Escandon Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories Priya Sriraman, Ph.D., Principal Investigator, Biotherapeutics Development, ENGINEERING Vaishnavi Ganti, Ph.D., Associate Principal Scientist, Biologics Discovery- Celgene Corp STREAM DMPK, Merck Research Laboratories SC2: Translational Considerations for Development of Monoclonal Veronica Juan, Ph.D., Principal Scientist, Protein Sciences, Merck Research ONCOLOGY Antibodies Part I: Focus on Early Discovery Labs STREAM Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Scott L. Klakamp, Ph.D., Vice President of Chemistry and Biochemistry, Pharmaceuticals Bioptix IMMUNOTHERAPY Enrique Escandon Ph.D., Senior Principal Scientist, DMPK and Disposition, Mohammad Tabrizi, Ph.D., Director Biologics Discovery, Merck Research STREAM Merck Research Laboratories Laboratories Vaishnavi Ganti, Ph.D., Associate Principal Scientist, Biologics Discovery- DMPK, Merck Research Laboratories SC8: In silico Immunogenicity Predictions – A Hands-On Workshop EXPRESSION Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intrexon STREAM Veronica Juan, Ph.D., Principal Scientist, Protein Sciences, Merck Research Labs Corp. Scott L. Klakamp, Ph.D., Principal, SKD Consulting LLC ANALYTICAL SC9: Target Selection for Biologics STREAM Mohammad Tabrizi, Ph.D., Director Biologics Discovery, Merck Research William R.